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A B S T R A C T
Much biomedical research is observational. The reporting of such research is often
inadequate, which hampers the assessment of its strengths and weaknesses and of a study’s
generalisability. The Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) Initiative developed recommendations on what should be included in an accurate
and complete report of an observational study. We defined the scope of the recommendations
to cover three main study designs: cohort, case-control, and cross-sectional studies. We
convened a 2-day workshop in September 2004, with methodologists, researchers, and journal
editors to draft a checklist of items. This list was subsequently revised during several meetings
of the coordinating group and in e-mail discussions with the larger group of STROBE
contributors, taking into account empirical evidence and methodological considerations. The
workshop and the subsequent iterative process of consultation and revision resulted in a
checklist of 22 items (the STROBE Statement) that relate to the title, abstract, introduction,
methods, results, and discussion sections of articles. 18 items are common to all three study
designs and four are specific for cohort, case-control, or cross-sectional studies. A detailed
Explanation and Elaboration document is published separately and is freely available on the
Web sites of PLoS Medicine, Annals of Internal Medicine, and Epidemiology. We hope that the
STROBE Statement will contribute to improving the quality of reporting of observational
studies.
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Introduction
Many questions in medical research are investigated in
observational studies [1]. Much of the research into the cause
of diseases relies on cohort, case-control, or cross-sectional
studies. Observational studies also have a role in research into
the beneﬁts and harms of medical interventions [2]. Rando-
mised trials cannot answer all important questions about a
given intervention. For example, observational studies are
more suitable to detect rare or late adverse effects of
treatments, and are more likely to provide an indication of
what is achieved in daily medical practice [3].
Research should be reported transparently so that readers
can follow what was planned, what was done, what was found,
and what conclusions were drawn. The credibility of research
depends on a critical assessment by others of the strengths
and weaknesses in study design, conduct, and analysis.
Transparent reporting is also needed to judge whether and
how results can be included in systematic reviews [4,5].
However, in published observational research important
information is often missing or unclear. An analysis of
epidemiological studies published in general medical and
specialist journals found that the rationale behind the choice
of potential confounding variables was often not reported [6].
Only few reports of case-control studies in psychiatry
explained the methods used to identify cases and controls
[7]. In a survey of longitudinal studies in stroke research, 17 of
49 articles (35%) did not specify the eligibility criteria [8].
Others have argued that without sufﬁcient clarity of report-
ing, the beneﬁts of research might be achieved more slowly
[9], and that there is a need for guidance in reporting
observational studies [10,11].
Recommendations on the reporting of research can
improve reporting quality. The Consolidated Standards of
Reporting Trials (CONSORT) Statement was developed in
1996 and revised 5 years later [12]. Many medical journals
supported this initiative [13], which has helped to improve
the quality of reports of randomised trials [14,15]. Similar
initiatives have followed for other research areas—e.g., for
the reporting of meta-analyses of randomised trials [16] or
diagnostic studies [17]. We established a network of method-
ologists, researchers, and journal editors to develop recom-
mendations for the reporting of observational research: the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) Statement.
Aims and Use of the STROBE Statement
The STROBE Statement is a checklist of items that should
be addressed in articles reporting on the 3 main study designs
of analytical epidemiology: cohort, case-control, and cross-
sectional studies. The intention is solely to provide guidance
on how to report observational research well: these recom-
mendations are not prescriptions for designing or conduct-
ing studies. Also, while clarity of reporting is a prerequisite to
evaluation, the checklist is not an instrument to evaluate the
quality of observational research.
Here we present the STROBE Statement and explain how it
was developed. In a detailed companion paper, the Explan-
ation and Elaboration article [18–20], we justify the inclusion
of the different checklist items and give methodological
background and published examples of what we consider
transparent reporting. We strongly recommend using the
STROBE checklist in conjunction with the explanatory
article, which is available freely on the Web sites of PLoS
Medicine (http://www.plosmedicine.org/), Annals of Internal
Medicine (http://www.annals.org/), and Epidemiology (http://
www.epidem.com/).
Development of the STROBE Statement
We established the STROBE Initiative in 2004, obtained
funding for a workshop and set up a Web site (http://www.
strobe-statement.org/). We searched textbooks, bibliographic
databases, reference lists, and personal ﬁles for relevant
material, including previous recommendations, empirical
studies of reporting and articles describing relevant meth-
odological research. Because observational research makes
use of many different study designs, we felt that the scope of
STROBE had to be clearly deﬁned early on. We decided to
focus on the 3 study designs that are used most widely in
analytical observational research: cohort, case-control, and
cross-sectional studies.
We organised a 2-day workshop in Bristol, UK, in
September 2004. 23 individuals attended this meeting,
including editorial staff from Annals of Internal Medicine,
BMJ, Bulletin of the World Health Organization, International
Journal of Epidemiology, JAMA, Preventive Medicine, and The
Lancet, as well as epidemiologists, methodologists, statisti-
cians, and practitioners from Europe and North America.
Written contributions were sought from 10 other individuals
who declared an interest in contributing to STROBE, but
could not attend. Three working groups identiﬁed items
deemed to be important to include in checklists for each type
of study. A provisional list of items prepared in advance
(available from our Web site) was used to facilitate dis-
cussions. The 3 draft checklists were then discussed by all
participants and, where possible, items were revised to make
them applicable to all three study designs. In a ﬁnal plenary
session, the group decided on the strategy for ﬁnalizing and
disseminating the STROBE Statement.
After the workshop we drafted a combined checklist
including all three designs and made it available on our
Web site. We invited participants and additional scientists
and editors to comment on this draft checklist. We
subsequently published 3 revisions on the Web site, and 2
summaries of comments received and changes made. During
this process the coordinating group (i.e., the authors of the
present paper) met on eight occasions for 1 or 2 days and
held several telephone conferences to revise the checklist and
to prepare the present paper and the Explanation and
Elaboration paper [18–20]. The coordinating group invited 3
additional co-authors with methodological and editorial
expertise to help write the Explanation and Elaboration
paper, and sought feedback from more than 30 people, who
are listed at the end of this paper. We allowed several weeks
for comments on subsequent drafts of the paper and
reminded collaborators about deadlines by e-mail.
STROBE Components
The STROBE Statement is a checklist of 22 items that we
consider essential for good reporting of observational studies
(Table 1). These items relate to the article’s title and abstract
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Table 1. The STROBE Statement—Checklist of Items That Should Be Addressed in Reports of Observational Studies
Item
number
Recommendation
TITLE and ABSTRACT 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract
(b) Provide in the abstract an informative and balanced summary of what was done and what was found
INTRODUCTION
Background/
rationale
2 Explain the scientific background and rationale for the investigation being reported
Objectives 3 State specific objectives, including any prespecified hypotheses
METHODS
Study design 4 Present key elements of study design early in the paper
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of
follow-up
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give
the rationale for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed
Case-control study—For matched studies, give matching criteria and the number of controls per case
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/
measurement
8* For each variable of interest, give sources of data and details of methods of assessment (measurement).
Describe comparability of assessment methods if there is more than one group
Bias 9 Describe any efforts to address potential sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative
variables
11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why
Statistical
methods
12 (a) Describe all statistical methods, including those used to control for confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Case-control study—If applicable, explain how matching of cases and controls was addressed
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy
(e) Describe any sensitivity analyses
RESULTS
Participants 13* (a) Report the numbers of individuals at each stage of the study—e.g., numbers potentially eligible, examined for eligibility, con-
firmed eligible, included in the study, completing follow-up, and analysed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
Descriptive
data
14* (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential con-
founders
(b) Indicate the number of participants with missing data for each variable of interest
(c) Cohort study—Summarise follow-up time (e.g., average and total amount)
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time
Case-control study—Report numbers in each exposure category, or summary measures of exposure
Cross-sectional study—Report numbers of outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval).
Make clear which confounders were adjusted for and why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other
analyses
17 Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses
DISCUSSION
Key results 18 Summarise key results with reference to study objectives
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude
of any potential bias
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar stu-
dies, and other relevant evidence
Generalisability 21 Discuss the generalisability (external validity) of the study results
OTHER INFORMATION
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the
present article is based
*Give such information separately for cases and controls in case-control studies, and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist
is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and
Epidemiology at http://www.epidem.com/). Separate versions of the checklist for cohort, case-control, and cross-sectional studies are available on the STROBE Web site at http://www.
strobe-statement.org/.
doi:10.1371/journal.pmed.0040296.t001
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(item 1), the introduction (items 2 and 3), methods (items 4–
12), results (items 13–17) and discussion sections (items 18–
21), and other information (item 22 on funding). 18 items are
common to all three designs, while four (items 6, 12, 14, and
15) are design-speciﬁc, with different versions for all or part
of the item. For some items (indicated by asterisks),
information should be given separately for cases and controls
in case-control studies, or exposed and unexposed groups in
cohort and cross-sectional studies. Although presented here
as a single checklist, separate checklists are available for each
of the 3 study designs on the STROBE Web site.
Implications and Limitations
The STROBE Statement was developed to assist authors
when writing up analytical observational studies, to support
editors and reviewers when considering such articles for
publication, and to help readers when critically appraising
published articles. We developed the checklist through an
open process, taking into account the experience gained with
previous initiatives, in particular CONSORT. We reviewed
the relevant empirical evidence as well as methodological
work, and subjected consecutive drafts to an extensive
iterative process of consultation. The checklist presented
here is thus based on input from a large number of
individuals with diverse backgrounds and perspectives. The
comprehensive explanatory article [18–20], which is intended
for use alongside the checklist, also beneﬁted greatly from
this consultation process.
Observational studies serve a wide range of purposes, on a
continuum from the discovery of new ﬁndings to the
conﬁrmation or refutation of previous ﬁndings [18–20]. Some
studies are essentially exploratory and raise interesting
hypotheses. Others pursue clearly deﬁned hypotheses in
available data. In yet another type of studies, the collection of
new data is planned carefully on the basis of an existing
hypothesis. We believe the present checklist can be useful for
all these studies, since the readers always need to know what
was planned (and what was not), what was done, what was
found, and what the results mean. We acknowledge that
STROBE is currently limited to three main observational
study designs. We would welcome extensions that adapt the
checklist to other designs—e.g., case-crossover studies or
ecological studies—and also to speciﬁc topic areas. Four
extensions are now available for the CONSORT statement
[21–24]. A ﬁrst extension to STROBE is underway for gene-
disease association studies: the STROBE Extension to Genetic
Association studies (STREGA) initiative [25]. We ask those
who aim to develop extensions of the STROBE Statement to
contact the coordinating group ﬁrst to avoid duplication of
effort.
The STROBE Statement should not be interpreted as an
attempt to prescribe the reporting of observational research
in a rigid format. The checklist items should be addressed in
sufﬁcient detail and with clarity somewhere in an article, but
the order and format for presenting information depends on
author preferences, journal style, and the traditions of the
research ﬁeld. For instance, we discuss the reporting of
results under a number of separate items, while recognizing
that authors might address several items within a single
section of text or in a table. Also, item 22, on the source of
funding and the role of funders, could be addressed in an
appendix or in the methods section of the article. We do not
aim at standardising reporting. Authors of randomised
clinical trials were asked by an editor of a specialist medical
journal to ‘‘CONSORT’’ their manuscripts on submission
[26]. We believe that manuscripts should not be ‘‘STROBEd’’,
in the sense of regulating style or terminology. We encourage
authors to use narrative elements, including the description
of illustrative cases, to complement the essential information
about their study, and to make their articles an interesting
read [27].
We emphasise that the STROBE Statement was not
developed as a tool for assessing the quality of published
observational research. Such instruments have been devel-
oped by other groups and were the subject of a recent
systematic review [28]. In the Explanation and Elaboration
paper, we used several examples of good reporting from
studies whose results were not conﬁrmed in further research
– the important feature was the good reporting, not whether
the research was of good quality. However, if STROBE is
adopted by authors and journals, issues such as confounding,
bias, and generalisability could become more transparent,
which might help temper the over-enthusiastic reporting of
new ﬁndings in the scientiﬁc community and popular media
[29], and improve the methodology of studies in the long
term. Better reporting may also help to have more informed
decisions about when new studies are needed, and what they
should address.
We did not undertake a comprehensive systematic review
for each of the checklist items and sub-items, or do our own
research to ﬁll gaps in the evidence base. Further, although
no one was excluded from the process, the composition of the
group of contributors was inﬂuenced by existing networks
and was not representative in terms of geography (it was
dominated by contributors from Europe and North America)
and probably was not representative in terms of research
interests and disciplines. We stress that STROBE and other
recommendations on the reporting of research should be
seen as evolving documents that require continual assess-
ment, reﬁnement, and, if necessary, change. We welcome
suggestions for the further dissemination of STROBE—e.g.,
by re-publication of the present article in specialist journals
and in journals published in other languages. Groups or
individuals who intend to translate the checklist to other
languages should consult the coordinating group beforehand.
We will revise the checklist in the future, taking into account
comments, criticism, new evidence, and experience from its
use. We invite readers to submit their comments via the
STROBE Web site (http://www.strobe-statement.org/).
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